Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma

被引：4
|
作者：
Louvet, Cedric [1 ]
Nadeem, Omar [1 ]
Smith, Eric L. [1 ]
机构：
[1] Dana Farber Canc Ctr, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
来源：
BLOOD CANCER DISCOVERY | 2021年 / 2卷 / 04期
关键词：
D O I：
10.1158/2643-3230.BCD-21-0073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BCMA/CD3 epsilon-targeted bispecific antibody (BsAb) therapy represents a promising T cell-redirecting immunotherapy to treat relapsed and refractory multiple myeloma. However, rational combination strategies will most likely be key to achieve a long-lasting immune response. In this issue, Meermeier and colleagues investigate BsAb therapy in a syngeneic multiple myeloma model and elucidate that partnering with cyclophosphamide is associated with tempered activation, mitigated exhaustion of T cells, and is superior to pomalidomide or bort-ezomib in enhancing durable anti-multiple myeloma efficacy.
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [1] Infectious complications of bispecific antibody therapy in patients with multiple myeloma
    Sim, Beatrice Z.
    Longhitano, Anthony
    Er, Jeremy
    Harrison, Simon J.
    Slavin, Monica A.
    Teh, Benjamin W.
    [J]. BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [2] Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma
    Sim, Beatrice Z.
    Longhitano, Anthony
    Er, Jeremy
    Harrison, Simon J.
    Slavin, Monica
    Teh, Benjamin W.
    [J]. BLOOD, 2022, 140 : 4384 - 4385
  • [3] Infectious complications of bispecific antibody therapy in patients with multiple myeloma
    Beatrice Z. Sim
    Anthony Longhitano
    Jeremy Er
    Simon J. Harrison
    Monica A. Slavin
    Benjamin W. Teh
    [J]. Blood Cancer Journal, 13
  • [4] Kinetics of humoral immunodeficiency with bispecific antibody therapy in multiple myeloma.
    Hammons, Lindsay
    Szabo, Aniko
    Dhakal, Binod
    Radhakrishnan, Sabarinath Venniyil
    Chhabra, Saurabh
    D'Souza, Anita
    Mohan, Meera
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
    Hammons, Lindsay R.
    Szabo, Aniko
    Janardan, Abhishek
    Dhakal, Binod
    Chhabra, Saurabh
    D'Souza, Anita
    Mohan, Meera
    [J]. JAMA NETWORK OPEN, 2022, 5 (10) : E2238961
  • [6] A BCMA-TARGETED BISPECIFIC ANTIBODY IS ACTIVE IN MULTIPLE MYELOMA
    不详
    [J]. CANCER DISCOVERY, 2021, 11 (10) : 2366 - 2366
  • [7] Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
    Tacchetti, Paola
    Talarico, Marco
    Barbato, Simona
    Pantani, Lucia
    Mancuso, Katia
    Rizzello, Ilaria
    Zamagni, Elena
    Cavo, Michele
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (06) : 379 - 395
  • [8] Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma
    Shrestha, Asis
    Thostenson, Jeff
    Patel, Tanvi
    Bachu, Ramya
    Naqvi, Syed
    Trikannad, Anup Kumar
    Cheema, Hira Imad
    Shrivastava, Trilok
    Thanendrarajan, Sharmilan
    Al Hadidi, Samer
    Zangari, Maurizio
    van Rhee, Frits
    Schinke, Carolina D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future
    Holstein, Sarah A.
    Grant, Shakira J.
    Wildes, Tanya M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (27) : 4416 - +
  • [10] Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma
    Liu, Lawrence
    Goldsmith, Scott R.
    Leahey, Sheryl
    Luna, Carlos Gomez
    Streeter, Shawn
    Braun, Adam
    Nathwani, Nitya
    Rosenzweig, Michael
    Sahebi, Firoozeh
    Borogovac, Azra
    Keats, Jonathan
    Htut, Myo
    Chowdhury, Arnab
    Dadwal, Sanjeet Singh
    Krishnan, Amrita
    Janakiram, Murali
    [J]. BLOOD, 2023, 142
12345